AbbVie may see less pain from Humira sales decline as rival lags
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
AbbVie (ABBV) climbs after raising full-year earnings guidance
July 27, 2023 9:09 AM EDTAbbVie (NYSE: ABBV) shares are climbing premarket on the back of its second-quarter profit and revenue beat. The company also raised earnings per share guidance.
The pharmaceutical firm reported Q2 EPS of $2.91, $0.04 better than the analyst estimate of $2.87. Revenue for the quarter... More
